Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP

Conclusion of study: Bleomycin and vincristine discontinuation because of drug-specific adverse effects does not affect the efficacy of BEACOPP treatment in this setting.